argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
April 28, 2022
Breda, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2022 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website atargenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Use the access code 073235 to join the call. Please dial in 15 minutes prior to the live call.
Belgium | 32 800 548 13 |
United Kingdom | 44 808 189 6484 |
United States | 1 844 200 6205 |
All other locations | 1 929 526 1599 |
About argenx |
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,Twitter, andInstagram.
For further information, please contact:
Media:
Kelsey Kirkkkirk@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
arGEN-X SE published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 08:14:08 UTC.